Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
5
Neutral
4
Bullish
5
Bearish
11
Neutral
4
Bullish
31
Bearish
6
Neutral
0
Bullish
26
Bearish
5
Neutral
4
Bullish
5
Bearish
5
Neutral
4
Bullish
5
Bearish
6
Neutral
0
Bullish
26
Bearish
6
Neutral
0
Bullish
26
Bearish
6
Neutral
0
Bullish
26
Parmax Pharma Ltd, established in 1994, focuses on Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations (CMO).
The company initially manufactured antibiotics and speciality chemicals but discontinued business activities for some years before focusing on the current pharmaceutical operations.
Located in Gujarat, Parmax's antibiotic manufacturing plant has an installed capacity of 96 TPA, highlighting its production potential.
The company's historical expertise lies in manufacturing bulk drugs such as Amoxycillin and Ampicillin, indicating solid foundations in the pharmaceutical industry.
Promoted by industry veterans, Parmax Pharma's strategic decisions showed resilience and adaptability in a challenging business landscape.
Pharmaceuticals & Biotechnology
Pharmaceuticals
94 Cr
Low Risk
-78.9
34.8
—
20.4
139.10
22.60
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
92.00 | 102 Cr | 25.74 | 1.73 | 0.22 | 9.79 | 13.29 | 4.71 | ||
49.27 | 99 Cr | 64.40 | 4.30 | 0.00 | 2.96 | 6.55 | 3.46 | ||
136.40 | 94 Cr | -78.85 | 20.42 | 0.00 | 67.65 | -85.76 | -4.24 | ||
6.87 | 93 Cr | 21.88 | 1.19 | 0.00 | 6.03 | 8.35 | 3.45 | ||
44.99 | 90 Cr | 8.02 | 1.12 | 1.11 | 13.48 | 18.36 | 12.76 | ||
68.06 | 90 Cr | 43.74 | 1.92 | 0.00 | 2.17 | 5.12 | 2.74 | ||
731.05 | 88 Cr | 21.04 | 1.51 | 0.48 | 8.32 | 10.75 | 5.27 | ||
| Median: 7 Co. | — | 68.06 | 93 Cr | 21.88 | 1.73 | 0.00 | 8.32 | 8.35 | 3.46 |
Parmax Pharma Ltd (PARMAX) is currently trading at 136.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Parmax Pharma Ltd, established in 1994, focuses on Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations (CMO). The company initially manufactured antibiotics and speciality chemicals but discontinued business activities for some years before focusing on the current pharmaceutical operations. Located in Gujarat, Parmax's antibiotic manufacturing plant has an installed capacity of 96 TPA, highlighting its production potential. The company's historical expertise lies in manufacturing bulk drugs such as Amoxycillin and Ampicillin, indicating solid foundations in the pharmaceutical industry. Promoted by industry veterans, Parmax Pharma's strategic decisions showed resilience and adaptability in a challenging business landscape.
Over the past 52 weeks, Parmax Pharma Ltd has traded between a low of ₹22.60 and a high of ₹139.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Parmax Pharma Ltd has a market capitalization of approximately 93.83. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Parmax Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -78.85 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 93.83 Cr, Parmax Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Parmax Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Parmax Pharma Ltd is -78.85. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with persons acting in concert (PACs), acquired 11,52,450 equity shares in an off-market transaction.
The disclosed open offer price is ₹42.80 per equity share, payable in cash.
The board meeting is scheduled for Friday, August 14, 2026, to consider and approve unaudited standalone results for the quarter ended June 30, 2026.
Parmax Pharma said its board will meet on Friday, August 14, 2026, to approve unaudited standalone financial results for the quarter ended June 30, 2026.
